Reuters logo
BRIEF-Puma Biotechnology announces FDA advisory committee to review neratinib for extended adjuvant treatment of HER2-positive early stage breast cancer
April 17, 2017 / 12:32 PM / 8 months ago

BRIEF-Puma Biotechnology announces FDA advisory committee to review neratinib for extended adjuvant treatment of HER2-positive early stage breast cancer

April 17 (Reuters) - Puma Biotechnology Inc

* Puma Biotechnology announces FDA advisory committee to review neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer

* Puma Biotechnology - FDA scheduled new drug application for neratinib for discussion by oncologic drugs advisory committee on May 24, 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below